CellCentric

About:

CellCentric is a biotechnology company that targets at deubiquitinase (DUB) enzyme for cancer therapy.

Top Investors: Pfizer, RA Capital Management, Future Planet Capital, Innovate UK, UK Innovation & Science Seed Fund

Description:

CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga. The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.

Total Funding Amount:

$136M

Headquarters Location:

Cambridge, Cambridgeshire, United Kingdom

Founded Date:

2003-01-01

Founders:

Will West

Number of Employees:

1-10

Last Funding Date:

2024-07-24

IPO Status:

Private

Industries: